Trials / Completed
CompletedNCT04742361
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
Phase III Study of [18F]PSMA-1007 Positron Emission Tomography for the Detection of Prostate Cancer Lesions in Patients With Biochemical Recurrence After Previous Definitive Treatment for Localized Prostate Cancer
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 136 (actual)
- Sponsor
- ABX advanced biochemical compounds GmbH · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the diagnostic performance and safety of \[18F\]PSMA-1007 PET/CT imaging in patients with suspected recurrence of prostate cancer after previous definitive treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [18F]PSMA-1007 | diagnostic radiopharmaceutical for PET scan |
Timeline
- Start date
- 2021-08-27
- Primary completion
- 2023-06-23
- Completion
- 2025-05-05
- First posted
- 2021-02-08
- Last updated
- 2025-07-15
Locations
6 sites across 3 countries: United States, Netherlands, Switzerland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04742361. Inclusion in this directory is not an endorsement.